[go: up one dir, main page]

WO2010074271A1 - Agent thérapeutique pour le diabète - Google Patents

Agent thérapeutique pour le diabète Download PDF

Info

Publication number
WO2010074271A1
WO2010074271A1 PCT/JP2009/071693 JP2009071693W WO2010074271A1 WO 2010074271 A1 WO2010074271 A1 WO 2010074271A1 JP 2009071693 W JP2009071693 W JP 2009071693W WO 2010074271 A1 WO2010074271 A1 WO 2010074271A1
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitor
salt
dpp
biguanide
gpr119 agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2009/071693
Other languages
English (en)
Japanese (ja)
Inventor
善行 辻畑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of WO2010074271A1 publication Critical patent/WO2010074271A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/133—Amines having hydroxy groups, e.g. sphingosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a novel medicament for preventing or treating diabetes or obesity, a pancreatic protective agent and the like.
  • Diabetes is one of the metabolic diseases characterized by high blood glucose levels resulting from abnormal sugar metabolism. This disease is broadly classified into type 1 diabetes, also called insulin dependent diabetes or IDDM, and type 2 diabetes, also called non-insulin dependent diabetes or NIDDM. Diabetes not only causes microvascular complications (eg diabetic retinopathy, diabetic neuropathy, diabetic nephropathy) but also macrovascular disorders (eg arteriosclerosis, cardiovascular disease, myocardial infarction) ) Risk factor. There are various causes of diabetes, such as insulin resistance, insulin secretion deficiency due to pancreatic ⁇ -cell dysfunction, etc., and increased gluconeogenesis in the liver, and treatment based on each cause is necessary.
  • IDDM insulin dependent diabetes
  • NIDDM non-insulin dependent diabetes
  • Insulin resistance and insulin secretion failure are closely related to obesity, dyslipidemia, hypertension, and the like, and are also the onset factors of complex metabolic diseases called metabolic syndrome.
  • Insulin preparations, SU agents, ⁇ -glucosidase inhibitors, biguanides, insulin sensitivity enhancers, etc. are used as therapeutic agents for diabetes depending on the type of disease and onset factors. There are limited patients who can reduce blood sugar to the level.
  • new drugs that have both high efficacy and safety are eagerly desired.
  • GPR119 which is found as a G protein-coupled receptor that is strongly expressed in pancreatic ⁇ cells, functions as a blood glucose sensor that promotes insulin secretion depending on the sugar concentration in the blood ( Non-patent document 1). Therefore, GPR119 has attracted attention as a new target molecule for the treatment of diabetes, and several GPR119 agonists have already been found (see Non-Patent Documents 2 to 4 and Patent Documents 1 to 4). Furthermore, GPR119 is also expressed in the intestinal tract, and the GPR119 agonist promotes GLP-1 secretion, and the GPR119 agonist AR231453 and sitagliptin are combined to give GLP119 agonist blood GLP.
  • Patent Document 6 discloses 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4-dioxo-1 (2H) -pyrimidinyl. ]] Methyl] -benzonitrile or a salt thereof and a biguanide or ⁇ -glucosidase inhibitor are disclosed.
  • Patent Document 7 discloses the first part: 2-[[6-[(3R) -3- Amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4-dioxo-1 (2H) -pyrimidinyl] methyl] -benzonitrile or a salt thereof and substantially containing metformin hydrochloride And the second part: containing metformin hydrochloride and 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4- Dioxo-1 (2 ) - pyrimidinyl] methyl] - it discloses a benzonitrile or solid preparation containing portion, containing substantially no salts thereof.
  • An object of the present invention is to provide a medicament, pancreatic protective agent, etc. for preventing or treating diabetes or obesity that exhibits high therapeutic effects and has few side effects.
  • the inventor has combined (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor (ie, (1) a DPP-IV inhibitor, (2) GPR119 Unexpectedly superior blood GLP-1 by combination of agonist and (3) biguanide, or (1) DPP-IV inhibitor, (2) GPR119 agonist and (3) ⁇ -glucosidase inhibitor) It has been found that synergistic effects of concentration increasing action, pancreatic insulin content increasing action and plasma PYY amount increasing action can be obtained, an extremely high diabetes and obesity treatment effect can be expected, and excellent pancreatic protective action can be achieved. It came to complete.
  • the present invention [1] A drug for the prevention or treatment of diabetes or obesity (hereinafter referred to as “the combination of a (1) DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor” It is also referred to as “the preventive or therapeutic agent of the present invention” [2] Pancreatic protective agent (hereinafter also referred to as “pancreatic protective agent of the present invention”) comprising a combination of (1) DPP-IV inhibitor, (2) GPR119 agonist and (3) biguanide or ⁇ -glucosidase inhibitor.
  • the preventive or therapeutic agent of the present invention and “the pancreatic protective agent of the present invention” are collectively referred to as “the combination agent of the present invention”).
  • the combination agent of the present invention [3] The pharmaceutical or agent according to [1] or [2] above, wherein the DPP-IV inhibitor is alogliptin or a salt thereof, [4] The pharmaceutical or agent according to [1] or [2] above, wherein the biguanide is metformin or a salt thereof, [5] The pharmaceutical or agent according to [1] or [2] above, wherein the ⁇ -glucosidase inhibitor is voglibose, [6] A method for preventing or treating diabetes or obesity, comprising administering (1) a DPP-IV inhibitor, (2) a GPR119 agonist, and (3) a biguanide or ⁇ -glucosidase inhibitor in combination.
  • a DPP-IV inhibitor Use of (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor for the manufacture of a medicament for the prevention or treatment of diabetes or obesity, [11] The use according to [10] above, wherein the DPP-IV inhibitor is alogliptin or a salt thereof, [12] The use according to [10] above, wherein the biguanide is metformin or a salt thereof. [13] The use according to [10] above, wherein the ⁇ -glucosidase inhibitor is voglibose.
  • a method for increasing blood GLP-1 content comprising administering (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor in combination.
  • a method of increasing plasma PYY content comprising administering a combination of (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor, [20] Use of (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor for the manufacture of a medicament for increasing blood GLP-1 content, [21] Use of (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor for the manufacture of a medicament for increasing plasma PYY content, [22] As a combined medicine for simultaneous, divided or sequential use in the prevention or treatment of diabetes or obesity, (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or a medicament containing an ⁇ -glucosidase inhibitor, [23] The medicament according to [22] above, characterized by (1) a DPP
  • the combination agent of the present invention has excellent blood GLP-1 increasing action, pancreatic insulin content increasing action and plasma PYY amount increasing action, and is useful for the prevention and treatment of diabetes and obesity.
  • the concomitant drug of the present invention has a pancreatic protective effect that suppresses pancreatic exhaustion caused by glycotoxicity, lipotoxicity, oxidative stress or endoplasmic reticulum stress due to diabetes, and is a sugar-dependent function that is an important function of pancreatic ⁇ cells The ability to secrete insulin.
  • the concomitant drug of the present invention can suppress pancreatic ⁇ cell death due to diabetes and promote pancreatic ⁇ cell neogenesis or replication.
  • the concomitant drug of the present invention induces sugar-dependent insulin secretion promotion, but there are side effects (eg, vascular complications, hypoglycemia) possessed by insulin preparations, and insulin secretory hypoglycemic agents that act on sulfonylurea receptors. Has no side effects (eg, pancreatic exhaustion, hypoglycemia). Therefore, the concomitant drug of the present invention can be safely administered over a long period to a patient suffering from diabetes or the like.
  • a DPP-IV inhibitor means a compound that binds to DPP-IV and inhibits its activity.
  • the compound may be either peptidic or non-peptidic, but is preferably a non-peptidic compound.
  • the DPP-IV inhibitor may have different forms before and after administration to the living body as long as the inhibitory activity is retained. That is, the DPP-IV inhibitor may be an “active metabolite” having DPP-IV inhibitory activity after becoming a structural change body after undergoing metabolism in vivo.
  • the DPP-IV inhibitor may be a “prodrug” that is converted into an active form by a reaction with an enzyme, gastric acid or the like under physiological conditions in vivo.
  • the DPP-IV inhibitor used in the present invention include alogliptin or a salt thereof (preferably benzoate), sitagliptin or a salt thereof, vildagliptin or a salt thereof, saxagliptin or a salt thereof, melogliptin or a salt thereof, dutogliptin or a salt thereof Salt, linagliptin or a salt thereof, TS-021 or a salt thereof, T-6666 or a salt thereof, SK-0403 or a salt thereof, PT-630 or a salt thereof, ABT-279 or a salt thereof, KRP-104 or a salt thereof, R -1579 or a salt thereof, PF-734200 or a salt thereof, BMS-686117 or a salt thereof, DSP-72
  • alogliptin or a salt thereof preferably benzoate
  • 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4- Dioxo-1 (2H) -pyrimidinyl] methyl] -4-fluorobenzonitrile or a salt thereof is preferred.
  • a GPR119 agonist means a compound that activates GPR119 by binding to GPR119 and induces an intracellular response mediated by GPR119.
  • the compound may be either peptidic or non-peptidic, and may be an endogenous ligand of GPR119, but is preferably a non-peptidic compound.
  • GPR119 agonists used in the present invention include AR231453, MBX-2982, PSN821, PSN-632408, PSN119-1, PSN119-1M, GSK252A, PSN375963, PSN632408, APD597, MBX-2982, AS1535907, AS1907417, etc.
  • biguanides used in the present invention include metformin, phenformin, buformin, or salts thereof (eg, hydrochloride, fumarate, succinate). Of these, metformin or a salt thereof (preferably hydrochloride) is preferable.
  • the ⁇ -glucosidase inhibitor used in the present invention include voglibose, acarbose, miglitol, emiglitate and the like. Of these, voglibose is preferable.
  • the “(1) DPP-IV inhibitor, (2) GPR119 agonist and (3) biguanide combination” of the present invention is preferably [1] (1) Alogliptin, sitagliptin, vildagliptin, saxagliptin, 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4-dioxo- 1 (2H) -pyrimidinyl] methyl] -4-fluorobenzonitrile, or a salt thereof (preferably alogliptin, 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4- Dihydro-3-methyl-2,4-dioxo-1 (2H) -pyrimidinyl] methyl] -4-fluorobenzonitrile, or a salt thereof), (2) a combination of a GPR119 agonist and (3) a biguanide; [2] A combination of
  • the “(1) DPP-IV inhibitor, (2) GPR119 agonist and (3) ⁇ -glucosidase inhibitor combination” of the present invention is preferably [1] (1) Alogliptin, sitagliptin, vildagliptin, saxagliptin, 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4-dihydro-3-methyl-2,4-dioxo- 1 (2H) -pyrimidinyl] methyl] -4-fluorobenzonitrile, or a salt thereof (preferably alogliptin, 2-[[6-[(3R) -3-amino-1-piperidinyl] -3,4- Dihydro-3-methyl-2,4-dioxo-1 (2H) -pyrimidinyl] methyl] -4-fluorobenzonitrile, or a salt thereof), (2) a GPR119 agonist and (3) an ⁇ -glucosidase inhibitor
  • the present invention preferably comprises: [A1] (1) Alogliptin or a salt thereof (preferably benzoate), (2) a GPR119 agonist and (3) a drug for the prevention or treatment of diabetes or obesity, which is a combination of metformin or a salt thereof ; [A2] (1) Alogliptin or a salt thereof (preferably benzoate), (2) a GPR119 agonist, and (3) a drug for the prevention or treatment of diabetes or obesity; [B1] (1) Alogliptin or a salt thereof (preferably benzoate), (2) a GPR119 agonist and (3) a pancreatic protective agent comprising a combination of metformin or a salt thereof; [B2] (1) Alogliptin or a salt thereof (preferably benzoate), (2) a GPR119 agonist, and (3) a pancreatic protective agent comprising voglibose; [C1] Prevention or treatment of diabetes or obesity comprising administering (1) alogliptin or a salt thereof (preferably benzoate), (2) a GPR119
  • DPP-IV inhibitors, GPR119 agonists, biguanides and ⁇ -glucosidase inhibitors may form salts.
  • the salt is preferably a pharmacologically acceptable salt, for example, a salt with an inorganic acid, a salt with an organic acid, a salt with a basic or acidic amino acid, and the like.
  • Preferable examples of the salt with inorganic acid include salts with hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid and the like.
  • Preferable examples of the salt with organic acid include acetic acid, trifluoroacetic acid, fumaric acid, oxalic acid, tartaric acid, maleic acid, citric acid, succinic acid, malic acid, methanesulfonic acid, benzoic acid, toluenesulfonic acid salt and the like.
  • Preferable examples of the salt with basic amino acid include a salt with arginine and the like.
  • Preferable examples of the salt with acidic amino acid include salts with aspartic acid, glutamic acid and the like.
  • the concomitant drug of the present invention is obtained by combining (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor as active ingredients. These active ingredients may be formulated separately or simultaneously with a pharmacologically acceptable carrier.
  • a pharmacologically acceptable carrier various organic or inorganic carrier substances commonly used as pharmaceutical materials are used, and excipients, lubricants, binders, disintegrants in solid preparations; solvents in liquid preparations , Solubilizing agents, suspending agents, isotonic agents, buffers, soothing agents and the like. If necessary, preparation additives such as preservatives, antioxidants, colorants, sweeteners and the like can also be used.
  • the excipient include lactose, sucrose, D-mannitol, D-sorbitol, starch, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropylcellulose, sodium carboxymethylcellulose, gum arabic, pullulan, light Anhydrous silicic acid, synthetic aluminum silicate, magnesium magnesium metasilicate, etc. are mentioned.
  • the lubricant include magnesium stearate, calcium stearate, talc, colloidal silica and the like.
  • Preferred examples of the binder include pregelatinized starch, sucrose, gelatin, gum arabic, methylcellulose, carboxymethylcellulose, sodium carboxymethylcellulose, crystalline cellulose, sucrose, D-mannitol, trehalose, dextrin, pullulan, hydroxypropylcellulose, hydroxy Examples thereof include propylmethylcellulose and polyvinylpyrrolidone.
  • Preferable examples of the disintegrant include lactose, sucrose, starch, carboxymethyl cellulose, carboxymethyl cellulose calcium, croscarmellose sodium, carboxymethyl starch sodium, light anhydrous silicic acid, low substituted hydroxypropyl cellulose and the like.
  • the solvent include water for injection, physiological saline, Ringer's solution, alcohol, propylene glycol, polyethylene glycol, sesame oil, corn oil, olive oil, cottonseed oil and the like.
  • solubilizers include polyethylene glycol, propylene glycol, D-mannitol, trehalose, benzyl benzoate, ethanol, trisaminomethane, cholesterol, triethanolamine, sodium carbonate, sodium citrate, sodium salicylate, sodium acetate. Etc.
  • suspending agent examples include surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate; for example, polyvinyl alcohol, polyvinyl Examples include hydrophilic polymers such as pyrrolidone, sodium carboxymethylcellulose, methylcellulose, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose; polysorbates, polyoxyethylene hydrogenated castor oil, and the like.
  • surfactants such as stearyltriethanolamine, sodium lauryl sulfate, laurylaminopropionic acid, lecithin, benzalkonium chloride, benzethonium chloride, and glyceryl monostearate
  • polyvinyl alcohol polyvinyl Examples include hydrophilic polymers such as pyrrolidone, sodium carboxymethylcellulose, methylcellulose,
  • Preferable examples of the isotonizing agent include sodium chloride, glycerin, D-mannitol, D-sorbitol, glucose and the like.
  • Preferable examples of the buffer include buffer solutions such as phosphate, acetate, carbonate, citrate and the like.
  • Preferable examples of the soothing agent include benzyl alcohol.
  • Preferable examples of the preservative include p-hydroxybenzoates, chlorobutanol, benzyl alcohol, phenethyl alcohol, dehydroacetic acid, sorbic acid and the like.
  • Preferable examples of the antioxidant include sulfite and ascorbate.
  • Preferred examples of the colorant include water-soluble edible tar dyes (eg, edible dyes such as edible red Nos.
  • sweetening agent examples include saccharin sodium, dipotassium glycyrrhizinate, aspartame, stevia and the like.
  • the three active ingredients of the present invention (1) DPP-IV inhibitor, (2) GPR119 agonist or (3) ⁇ -glucosidase inhibitor are known per se as methods for producing pharmaceutical formulations (eg, Japanese Pharmacy) According to the method described in the above), alone or mixed with a pharmacologically acceptable carrier, for example, tablets (including sugar-coated tablets, film-coated tablets, sublingual tablets, orally disintegrating tablets, buccal tablets, etc.), Pills, powders, granules, capsules (including soft capsules and microcapsules), troches, syrups, solutions, emulsions, suspensions, controlled-release preparations (eg, immediate-release preparations, sustained-release preparations) , Sustained-release microcapsules), aerosols, films (eg, orally disintegrating films, oral mucosal film), injections (eg, subcutaneous injections, intravenous injections, intramuscular injections, intraperitoneal injections) Agent), As drops, transdermal preparations, ointments, lotion
  • Orally or parenterally eg, intravenous, intramuscular, subcutaneous, intraorgan, intranasal, intradermal, instillation, intracerebral, rectal, intravaginal, intraperitoneal, intratumoral, proximal to tumor, etc. And direct administration to the lesion).
  • oral preparations an oral preparation excellent in convenience or compliance is preferable.
  • the total content of active ingredients (DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor) in the concomitant drug of the present invention varies depending on the type of active ingredient, the size of the preparation, etc. 90% by weight, preferably 5 to 80% by weight.
  • the mixing ratio of the DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor is appropriately selected depending on the administration subject, administration route, target disease, dosage form, drug combination, etc. be able to.
  • GPR119 agonist is usually used in an amount of about 0.005 to 200 parts by weight, preferably about 0.01 to 100 parts by weight
  • biguanide is usually used in an amount of 1 to 200 parts by weight with respect to 1 part by weight of the DPP-IV inhibitor.
  • GPR119 agonist is usually about 0.005 to 200 parts by weight, preferably 0.01 to 100 parts by weight per 1 part by weight of the DPP-IV inhibitor.
  • the ⁇ -glucosidase inhibitor may be used in an amount of usually about 0.001 to 1 part by weight, preferably about 0.005 to 0.2 part by weight.
  • the administration form of the concomitant drug of the present invention is not particularly limited, as long as the DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor are combined at the time of administration.
  • Examples of such administration forms include 1) administration of a single preparation obtained by simultaneously formulating a DPP-IV inhibitor, a GPR119 agonist and a biguanide or ⁇ -glucosidase inhibitor, 2) a DPP-IV inhibitor Co-administration of three formulations obtained by separately formulating a GPR119 agonist and a biguanide or ⁇ -glucosidase inhibitor by the same route of administration; 3) a DPP-IV inhibitor, a GPR119 agonist and a biguanide or ⁇ -glucosidase Administration of three types of preparations obtained by separately formulating inhibitors at different time intervals in the same administration route, 4) Formulating DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor separately Co-administration of three different preparations obtained by different routes of administration, 5) DPP-IV inhibitors Administration of GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor separately formulated at different time courses by different administration routes (D
  • the concomitant drug of the present invention has low toxicity and is safe, and is administered orally or parenterally to mammals (eg, human, mouse, rat, rabbit, dog, cat, cow, horse, pig, monkey). can do.
  • the dose of the concomitant drug of the present invention may be in accordance with the dose of the active ingredient DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor, and the administration subject, administration route, target disease, agent It can be appropriately selected depending on the shape, combination of drugs, and the like.
  • dosages of DPP-IV inhibitors, GPR119 agonists, biguanides and ⁇ -glucosidase inhibitors described below can be mentioned.
  • the dose of the DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor can be appropriately selected based on the clinically used dose.
  • the dose of the DPP-IV inhibitor is usually 0.01 to 500 mg / day, preferably 0.1 to 100 mg / day, for example, per adult patient (body weight 60 kg).
  • This amount can also be administered in 2 to 3 divided doses per day.
  • the effective amount of alogliptin is usually 1 to 100 mg / day, preferably 6.25 to 50 mg per adult patient (body weight 60 kg).
  • the dose of the GPR119 agonist is usually 0.01 to 1000 mg / day, preferably 0.1 to 500 mg / day, more preferably 1 to 20 mg / day per adult patient (body weight 60 kg), for example. This amount can also be administered in 2 to 3 divided doses per day.
  • the dosage of biguanide is usually 125 to 2550 mg / day, preferably 250 to 2550 mg / day per adult patient (body weight 60 kg).
  • the effective amount of metformin is usually 125 to 2550 mg / day, preferably 500, 750, 1000, 1500 mg / day, etc. per adult patient (body weight 60 kg).
  • the dose of the ⁇ -glucosidase inhibitor is usually 0.01 to 10 mg / day, preferably 0.1 to 5 mg / day, more preferably 0.1 to 2 mg / day per adult patient (body weight 60 kg), for example. Day.
  • the effective amount of voglibose is usually 0.01 to 10 mg / day, preferably 0.6, 0.9 mg / day per adult patient (body weight 60 kg). Etc. This amount can also be administered in 2 to 3 divided doses per day.
  • the combination agent of the present invention has an excellent effect of increasing blood GLP-1 and pancreatic insulin content by combining a DPP-IV inhibitor, a GPR119 agonist and a biguanide or ⁇ -glucosidase inhibitor, and as a result It exhibits a synergistic hypoglycemic effect.
  • hypoglycemic effect of DPP-IV inhibitor, GPR119 agonist and biguanide or ⁇ -glucosidase inhibitor means “hyperglycemic effect of DPP-IV inhibitor alone”, “GPR119 agonist alone Means a hypoglycemic effect superior to the sum of “hypoglycemic effect of biguanide alone” or “hyperglycemic effect of ⁇ -glucosidase alone”.
  • the combination agent of the present invention has excellent blood GLP-1 increasing action, pancreatic insulin content increasing action, plasma PYY amount increasing action and pancreatic protective action.
  • “increase in GLP-1 in blood” means blood in GLP-1 that retains incretin activity (eg, GLP-1 (7-36) amide and GLP-1 (7-37)). Means that the concentration increases.
  • the blood GLP-1 increasing action can be evaluated by measuring the blood GLP-1 level in the administration subject according to a method known per se, and an increase in the measured value means an increase in each action.
  • GLP-1 may be measured by any method as long as GLP-1 can be measured. Specifically, radioimmunoassay or enzyme immunoassay using one type of anti-GLP-1 antibody; or two types having different epitopes And an enzyme immunoassay using the anti-GLP-1 antibody.
  • pancreatic insulin content means the insulin content in the pancreas.
  • the “pancreatic insulin content” is determined by measuring insulin extracted from a pancreatic tissue of a test animal according to a method known per se according to a method known per se.
  • the method for measuring insulin may be any method as long as insulin can be measured. Specifically, radioimmunoassay or enzyme immunoassay using one type of anti-insulin antibody; or two types of anti-insulin antibodies having different epitopes are used. An enzyme immunoassay or the like is used.
  • the “pancreatic insulin content” can also be evaluated using pancreatic insulin mRNA or pancreatic ⁇ cell mass as an index.
  • the amount of pancreatic insulin mRNA and pancreatic ⁇ cells can be measured using a method known per se.
  • the method of tissue staining using an insulin antibody is generally used to measure the amount of pancreatic ⁇ cells.
  • tissue staining using an insulin antibody is generally used to measure the amount of pancreatic ⁇ cells.
  • in situ hybridization for detecting insulin mRNA, or for proteins that are selectively expressed in pancreatic ⁇ cells for example, a method of labeling an endogenous or exogenous substance that binds with high specificity and measuring the labeling activity after administering the label to a test animal may be used.
  • the endogenous or exogenous substance can be labeled with, for example, a radioisotope, a luminescent substance (low molecular compound or protein such as luciferase or GFP), a fluorescent substance, or the like.
  • the “pancreatic insulin content” can also be evaluated by a known method used for estimating the amount of residual pancreatic ⁇ cells. Examples of the method include a method of measuring active insulin or C-peptide in blood by performing a glucagon tolerance test. Alternatively, a glucose tolerance test can be performed instead of the glucagon tolerance test to measure active insulin or C-peptide in the blood. In addition, active insulin or C-peptide in the blood can be measured without performing a glucagon tolerance test.
  • “increase in the amount of plasma PYY” means that the concentration of PYY in the plasma, which shows an antifeedant activity, increases via the PYY receptor.
  • the effect of increasing the amount of plasma PYY can be evaluated by measuring the plasma PYY value in the administration subject according to a method known per se, and an increase in the measured value means an increase in each effect.
  • the PYY may be measured by any method as long as PYY can be measured. Specifically, a radioimmunoassay or enzyme immunoassay using one type of anti-PYY antibody; or two types of anti-PYY antibodies having different epitopes are used. An enzyme immunoassay or the like is used.
  • the “pancreatic protective action” means an action of suppressing pancreatic exhaustion caused by glycotoxicity, lipotoxicity, oxidative stress or endoplasmic reticulum stress due to diabetes.
  • the “pancreatic protective effect” can be evaluated by measuring the “pancreatic insulin content” and the amount of pancreatic ⁇ cells described above.
  • Examples of the concomitant drug of the present invention include diabetes [eg, type 1 diabetes, type 2 diabetes, type 1.5 diabetes (LADA (Lentic Autoimmune Diabetes in Ads)), gestational diabetes, insulin secretion deficiency type diabetes, obesity type diabetes, glucose tolerance Dysfunction (IGT (Impaired Glucose Tolerance)), IFG (Impaired Fasting Glucose), IFG (Impaired Fasting Glycaemia)], diabetic complications [eg, neuropathy, nephropathy, retinopathy, cataract, macrovascular disorder, , Osteopenia, diabetic hyperosmotic coma, infection (eg respiratory infection, urinary tract infection, digestive organ infection, skin soft tissue infection, lower limb infection), diabetic gangrene, dry mouth Disease, hearing loss, cerebrovascular disorder, peripheral blood circulation disorder] It can be used for prevention and treatment of Moreover, the concomitant drug of the present invention can suppress the progression from diabetes to diabetic complications (preferably diabetic neuropathy, diabetic
  • the concomitant drug of the present invention is used for mammals whose blood glucose level is higher than the normal level. Can be used for normalization of blood glucose level. Furthermore, the concomitant drug of the present invention is useful for mammals whose blood glucose level is higher than the normal level and whose pancreatic ( ⁇ cell) function is reduced and insulin secretion is incomplete. Moreover, the concomitant drug of the present invention can increase the amount of pancreatic insulin mRNA.
  • the concomitant drug of the present invention suppresses pancreatic exhaustion caused by glycotoxicity, lipotoxicity, glycolipotoxicity, oxidative stress or endoplasmic reticulum stress due to diabetes, and is a sugar-dependent insulin that is an important function of pancreatic ⁇ cells. Can retain secretory capacity. Furthermore, the concomitant drug of the present invention can suppress pancreatic ⁇ cell death due to diabetes, and can promote the formation or replication of pancreatic ⁇ cells. Furthermore, the concomitant drug of the present invention can promote the enlargement of pancreatic ⁇ cells.
  • concomitant drugs include antidiabetic drugs, diabetic complication drugs, antiobesity drugs, hypertension drugs, hyperlipidemia drugs, diuretics, antiarteriosclerotic drugs, antithrombotic drugs, arthritis drugs , Anti-anxiety drugs, antidepressants, neuropsychiatric drugs, sleep inducers and the like.
  • the administration time of the concomitant drug and the concomitant drug of the present invention is not limited, and these may be administered simultaneously to the administration subject or may be administered with a time difference. Furthermore, the concomitant drug and the concomitant drug of the present invention may be administered as four or more types of preparations containing the respective active ingredients, or may be administered as a single preparation containing both active ingredients.
  • the dose of the concomitant drug can be appropriately selected on the basis of the clinically used dose.
  • the mixing ratio of the concomitant drug and the concomitant drug of the present invention can be appropriately selected depending on the administration subject, administration route, target disease, symptom, combination and the like. For example, when the administration subject is a human, the concomitant drug may be used in an amount of 0.01 to 100 parts by weight with respect to 1 part by weight of the active ingredient in the combination agent of the present invention.
  • insulin preparations eg, animal insulin preparations extracted from bovine and porcine pancreas; human insulin preparations genetically engineered using Escherichia coli and yeast; insulin zinc; protamine insulin zinc; insulin Fragment or derivative (eg, INS-1), oral insulin preparation
  • insulin resistance improving agent eg, pioglitazone or a salt thereof (preferably hydrochloride), rosiglitazone or a salt thereof (preferably maleate)
  • Metaglidasen AMG-131, Balaglitazone, MBX-2044, Riboglitazone, Aleglitazar, Chiglitazar, Lobeglitazone, PLX-204, PN-2034 , GFT-505, THR-0921, WO2007 / 013694, WO2007 / 018314, WO2008 / 093639 or WO2008 / 0997 94 compounds
  • insulin secretagogues eg, sulfonylureas (
  • Examples of the “diabetic complication therapeutic agent” include aldose reductase inhibitors (eg, tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat (AS-3201), ridressat), neurotrophic factor and its increase drug (Eg, NGF, NT-3, BDNF, neurotrophin production / secretion promoter described in WO01 / 14372 (eg, 4- (4-chlorophenyl) -2- (2-methyl-1-imidazolyl) -5- [3- (2-methylphenoxy) propyl] oxazole), compounds described in WO2004 / 039365), PKC inhibitors (eg, ruboxistaurin mesylate), AGE inhibitors (eg, ALT946, N-phenol) Nasyl thiazolium bromide (ALT766), EXO-226, pyridoline (Pyridorin), pyridoxamine), GABA receptor agonist (e
  • anti-obesity agents examples include monoamine uptake inhibitors (eg, phentermine, sibutramine, mazindol, floxetine, and tesofensin), serotonin 2C receptor agonists (eg, lorcaserin), serotonin 6 receptor antagonist, histamine H3 receptor Body, GABA modulator (eg, topiramate), neuropeptide Y antagonist (eg, Berneperit), cannabinoid receptor antagonist (eg, rimonabant, taranaban), ghrelin antagonist, ghrelin receptor antagonist, ghrelin acylase Inhibitor, opioid receptor antagonist (eg, GSK-1521498), orexin receptor antagonist, melanocortin 4 receptor agonist, 11 ⁇ -hydroxysteroid dehydrogenase inhibitor (eg, AZD-4017), pancreatic lipase inhibitor (eg, Orlistat, cetilistat), ⁇ 3 agonists (eg, N-59), phentermine
  • GLP-1 eg, exenatide, liraglutide
  • amylin preparations eg, pramlintide, AC- 2307
  • neuropeptide Y agonists eg, PYY3-36, derivatives of PYY3-36, obineptide, TM-30339, TM-30335
  • oxyntomodulin preparations FGF21 preparations (eg, extracted from bovine, porcine pancreas) Animal FGF21 preparations; human FGF21 preparations genetically engineered using Escherichia coli and yeast; FGF21 fragments or derivatives)), antifeedants (eg, P-57) and the like.
  • hypotensive drug examples include angiotensin converting enzyme inhibitors (eg, captopril, enalapril, delapril, etc.), angiotensin II antagonists (eg, candesartan cilexetil, candesartan, losartan, losartan potassium, eprosartan, valsartan, telmisartan , Irbesartan, tasosartan, olmesartan, olmesartan, medoxomil, azilsartan, azilsartan, medoxomil, etc.), calcium antagonists (eg, manidipine, nifedipine, amlodipine, efonidipine, nicardipine, amlodipine, sinyldipine, etc.), ⁇ -blockers (eg, metoprolol, teprolol) Propranolol, carvedilol, pindo
  • diuretics examples include xanthine derivatives (eg, sodium salicylate theobromine, calcium salicylate theobromine, etc.), thiazide preparations (eg, etiazide, cyclopentiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benchylhydrochlorothiazide, penfluolide.
  • xanthine derivatives eg, sodium salicylate theobromine, calcium salicylate theobromine, etc.
  • thiazide preparations eg, etiazide, cyclopentiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benchylhydrochlorothiazide, penfluolide.
  • anti-aldosterone preparations eg, spironolactone, triamterene, etc.
  • carbonic anhydrase inhibitors eg, acetazolamide, etc.
  • chlorobenzenesulfonamide preparations eg, chlorthalidone, mefluside, indapamide, etc.
  • Azosemide is
  • hypolipidemic agent examples include HMG-CoA reductase inhibitors (eg, pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin, or salts thereof (eg, sodium salt, calcium salt)) Squalene synthase inhibitors (eg, compounds described in pamphlet of WO97 / 10224, for example, N-[[(3R, 5S) -1- (3-acetoxy-2,2-dimethylpropyl) -7-chloro- 5- (2,3-dimethoxyphenyl) -2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl] acetyl] piperidine-4-acetic acid), fibrate compounds (Eg, bezafibrate, clofibrate, simfibrate, clinofibrate), anion exchange resin (eg,
  • Examples of the “diuretic” include xanthine derivatives (eg, sodium salicylate theobromine, calcium salicylate theobromine), thiazide preparations (eg, etiazide, cyclopentiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benchylhydrochlorothiazide, penflutide, Polythiazide, meticlotiazide), anti-aldosterone formulation (eg, eplerenone, spironolactone, triamterene), carbonic anhydrase inhibitor (eg, acetazolamide), chlorobenzenesulfonamide-based formulation (eg, chlorthalidone, mefluside, indapamide), azosemide, isosorbide, Examples include ethacrynic acid, piretanide, bumetanide, furosemide and the like.
  • anti-atherosclerotic agent examples include acylcoenzyme A cholesterol acyltransferase (ACAT) inhibitors (eg, K-604), LpPLA2 inhibitors (eg, dalapradiv, rilapradib etc.), FLAP inhibitors (eg, AM103, AM803 etc.), 5LO inhibitors (eg, VIA-2291 etc.), sPLA2 inhibitors (eg, A-002), apoAI mimetic peptides (eg, D4F etc.), HDL preparations (eg, CSL-111 etc.), etc. Can be mentioned.
  • ACAT acylcoenzyme A cholesterol acyltransferase
  • LpPLA2 inhibitors eg, dalapradiv, rilapradib etc.
  • FLAP inhibitors eg, AM103, AM803 etc.
  • 5LO inhibitors eg, VIA-2291 etc.
  • sPLA2 inhibitors eg, A-002
  • antithrombotic agent examples include heparin (eg, heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium), warfarin (eg, warfarin potassium), antithrombin drug (eg, argatroban) (aragatroban), dabigatran), FXa inhibitors (eg, rivaroxaban, apixaban, edoxaban, YM150, WO02 / 06234, WO2004 / 048363, WO2005 / 030740, WO2005 / 058823 or WO2005 / 113504 compounds), thrombolytic drugs (eg, urokinase, tisokinase, alteplase, nateplase, monteplase, pamitepase (pamiteplase)), platelet aggregation inhibitors (eg Ticlopidine hydrochloride, clopidogrel, prasugrel
  • Examples of the “arthritis therapeutic agent” include ibuprofen and the like.
  • Examples of the “anti-anxiety agents” include alprazolam, etizolam, oxazolam, tandospirone, cloxazolam, clothiazepam, dichlorinated potassium chlorazepate, chlordiazepoxide, diazepam, fludiazepam, flutazolam, flutopazepam, prazepam, brozepampampamzem, , Ethyl loflazepate, lorazepam and the like.
  • antidepressant examples include tricyclic antidepressants (eg, imipramine, trimipramine, clomipramine, amitriptyline, nortriptyline, amoxapine, lofepramine, dosrepin, desipramine), tetracyclic antidepressants (eg, maprotiline, Mianserin, seriprine), selective serotonin uptake inhibitors (eg, fluoxetine, fluvoxamine, paroxetine, sertraline, escitalopram), serotonin and noradrenaline uptake inhibitors (eg, milnacipran, duloxetine, venlafaxine), trazodone, mirtazapine , Moclobecdo and the like.
  • tricyclic antidepressants eg, imipramine, trimipramine, clomipramine, amitriptyline, nortriptyline, amoxapine, lofepramine, dosrepin, des
  • Examples of the “psycho-neurological agent” include typical antipsychotic drugs (eg, clocapramine, chlorpromazine, phenobarbital, sultopride, thioprid, thioridazine, fluropamide, mosapramine, moperon, oxypertin, carpipramine, spiperone, sulpiride, zotepine, timiperone, Nemonapride, haloperidol, pimozide, prochlorperazine, propericazine, bromperidol, perphenazine, fluphenazine maleate, mizoribine, levomepromazine), atypical antipsychotics (eg, perospirone, olanzapine, quetiapine, risperidone, clozapine, Aripiprazole, ziprasidone, blonanserin, lurasidone) and the like.
  • the “sleep inducer” include, for example, ramelteon, GABA hypnotics (eg, brotizolam, estazolam, flurazepam, nitrazepam, triazolam, flunitrazepam, lormetazepam, rilmazaphone, quazepam, zopiclone, eszopicone, zolpidem, Non-GABA hypnotics (eg, eprivaserin, purvanserin, diphenhydramine, trazodone, doxepin) and the like.
  • GABA hypnotics eg, brotizolam, estazolam, flurazepam, nitrazepam, triazolam, flunitrazepam, lormetazepam, rilmazaphone, quazepam, zopiclone, eszopicone, zolpidem
  • the present invention further relates to “a therapeutic agent for diabetes and obesity comprising (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor”.
  • a therapeutic agent for diabetes and obesity comprising (1) a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a biguanide or ⁇ -glucosidase inhibitor.
  • “(1) DPP-IV inhibitors, (2) GPR119 agonists and (3) diabetes and obesity therapeutics containing biguanides or ⁇ -glucosidase inhibitors” are DPP-IV inhibitors, GPR119 agonists and Using a biguanide or an ⁇ -glucosidase inhibitor, it can be produced in the same manner as the combination agent of the present invention.
  • a DPP-IV inhibitor, (2) a GPR119 agonist and (3) a therapeutic agent for diabetes and obesity containing a biguanide or ⁇ -glucosidase inhibitor has an excellent effect of increasing blood GLP-1; It has an effect of increasing pancreatic insulin content and increasing the amount of plasma PYY, and can be used for patients requiring prevention and treatment of diabetes and obesity and pancreatic protection as well as the combination agent of the present invention. Further, “(1) DPP-IV inhibitor, (2) GPR119 agonist and (3) a therapeutic agent for diabetes and obesity containing biguanide or ⁇ -glucosidase inhibitor” is used in combination with the above combination drug You can also.
  • Reference example 1 The effect of GLP119 secretion promotion by combined use with GPR119 agonist and DPP-IV inhibitor in female Wistar fatty rats (WF rats) was examined. First, 25 15-week-old WF rats were divided into 5 groups of A to E, and blood was collected for measurement of blood GLP-1 level before drug administration.
  • a and alogliptin were orally administered at 10 mg / kg and 0.3 mg / kg, respectively. 60 minutes after compound administration, each individual was loaded with 1 g / kg of glucose by oral administration, blood was collected 10 minutes, 30 minutes, and 60 minutes after the load, and the amount of GLP-1 in the blood was measured with anti-GLP-1 antibody.
  • the enzyme immunoassay used Glucagon-Like Peptide-1 (Active) ELISA Kit [EGLP-35K]; MILLIPORE was examined. The results are shown in Table 1.
  • M formformin known as a biguanide
  • compound A and alogliptin are orally administered to group E at 10 mg / kg and 1 mg / kg, respectively
  • metformin and alogliptin are administered to group F, respectively.
  • 50 mg / kg and 1 mg / kg were orally administered
  • Group A was orally administered with Compound A, metformin and alogliptin 10 mg / kg, 50 mg / kg and 1 mg / kg, respectively.
  • 60 minutes after compound administration each individual was loaded with 1 g / kg of glucose by oral administration, and blood was collected before the load (0 minutes) and 10 minutes after the load.
  • voglibose known as an ⁇ -glucosidase inhibitor is orally administered at 0.03 mg / kg
  • Compound A and alogliptin are orally administered at 10 mg / kg and 0.3 mg / kg, respectively.
  • voglibose and alogliptin were orally administered at 0.03 mg / kg and 0.3 mg / kg, respectively
  • compound A, voglibose and alogliptin were respectively 10 mg / kg, 0.03 mg / kg and 0.3 mg. Per kg / kg.
  • voglibose known as an ⁇ -glucosidase inhibitor is orally administered at 0.03 mg / kg
  • Compound A and alogliptin are orally administered at 10 mg / kg and 0.3 mg / kg, respectively.
  • voglibose and alogliptin were orally administered at 0.03 mg / kg and 0.3 mg / kg, respectively
  • compound A, voglibose and alogliptin were respectively 10 mg / kg, 0.03 mg / kg and 0.3 mg. Per kg / kg.
  • the combination agent of the present invention has an excellent blood GLP-1 increasing action, pancreatic insulin content increasing action and plasma PYY amount increasing action, and is useful for the treatment of diabetes or obesity.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur un agent prophylactique ou thérapeutique pour le diabète ou l'obésité et sur un agent protecteur du pancréas, dont chacun peut présenter une efficacité thérapeutique élevée et a peu d'effets secondaires néfastes. L'invention porte spécifiquement sur une préparation pharmaceutique pour prévenir ou traiter le diabète ou l'obésité, qui comprend une combinaison de (1) un inhibiteur de DPP-IV, (2) un agoniste de GPR119 et (3) un biguanide ou un inhibiteur d'α-glucosidase. L'invention porte également spécifiquement sur un agent protecteur du pancréas comprenant une combinaison de (1) un inhibiteur de DPP-IV, (2) un agoniste de GPR119 et (3) un biguanide ou un inhibiteur d'α-glucosidase.
PCT/JP2009/071693 2008-12-26 2009-12-25 Agent thérapeutique pour le diabète Ceased WO2010074271A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008335141 2008-12-26
JP2008-335141 2008-12-26

Publications (1)

Publication Number Publication Date
WO2010074271A1 true WO2010074271A1 (fr) 2010-07-01

Family

ID=42287875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2009/071693 Ceased WO2010074271A1 (fr) 2008-12-26 2009-12-25 Agent thérapeutique pour le diabète

Country Status (1)

Country Link
WO (1) WO2010074271A1 (fr)

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008110964A (ja) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc 糖尿病および糖尿病に関連する状態の治療のため、ならびに血中ｇｌｐ−１レベルの増加によって改善される状態の治療のための併用療法
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
CN102918027A (zh) * 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
WO2014011926A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520226A (ja) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
WO2007033266A2 (fr) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
WO2008008887A2 (fr) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Composés chimiques
JP2008110964A (ja) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc 糖尿病および糖尿病に関連する状態の治療のため、ならびに血中ｇｌｐ−１レベルの増加によって改善される状態の治療のための併用療法
JP2008115080A (ja) * 2005-04-22 2008-05-22 Taisho Pharmaceutical Co Ltd 併用医薬
JP2008517921A (ja) * 2004-10-25 2008-05-29 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤
WO2008113000A1 (fr) * 2007-03-15 2008-09-18 Nectid, Inc. Combinaisons anti-diabétiques comprenant une composition de biguanide à libération lente et une composition d'inhibiteur de dipeptidyl peptidase iv à libération immédiate
WO2008130615A1 (fr) * 2007-04-20 2008-10-30 Schering Corporation Dérivés de tétrahydropyrido[4,3-d] pyrimidinone et procédés pour leur utilisation

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520226A (ja) * 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
JP2008517921A (ja) * 2004-10-25 2008-05-29 ノバルティス アクチエンゲゼルシャフト Ｄｐｐ−ｉｖ阻害剤、ｐｐａｒ抗糖尿病薬およびメトホルミンの組合わせ剤
JP2008110964A (ja) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc 糖尿病および糖尿病に関連する状態の治療のため、ならびに血中ｇｌｐ−１レベルの増加によって改善される状態の治療のための併用療法
JP2008115080A (ja) * 2005-04-22 2008-05-22 Taisho Pharmaceutical Co Ltd 併用医薬
WO2007033266A2 (fr) * 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Administration d'inhibiteurs de dipeptidyl peptidase
WO2008008887A2 (fr) * 2006-07-13 2008-01-17 Smithkline Beecham Corporation Composés chimiques
WO2008113000A1 (fr) * 2007-03-15 2008-09-18 Nectid, Inc. Combinaisons anti-diabétiques comprenant une composition de biguanide à libération lente et une composition d'inhibiteur de dipeptidyl peptidase iv à libération immédiate
WO2008130615A1 (fr) * 2007-04-20 2008-10-30 Schering Corporation Dérivés de tétrahydropyrido[4,3-d] pyrimidinone et procédés pour leur utilisation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CHU, Z.L. ET AL.: "A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release", ENDOCRINOLOGY, vol. 149, no. 5, 2008, pages 2038 - 2047 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8933083B2 (en) 2003-01-14 2015-01-13 Arena Pharmaceuticals, Inc. 1,2,3-trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto such as diabetes and hyperglycemia
JP2008110964A (ja) * 2005-01-10 2008-05-15 Arena Pharmaceuticals Inc 糖尿病および糖尿病に関連する状態の治療のため、ならびに血中ｇｌｐ−１レベルの増加によって改善される状態の治療のための併用療法
US8883714B2 (en) 2008-04-07 2014-11-11 Arena Pharmaceuticals, Inc. Pharmaceutical compositions comprising GPR119 agonists which act as peptide YY (PYY) secretagogues
US8293729B2 (en) 2009-06-24 2012-10-23 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
US8481731B2 (en) 2009-06-24 2013-07-09 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical composition and methods relating thereto
CN102918027A (zh) * 2010-04-06 2013-02-06 艾尼纳制药公司 Gpr119受体调节剂和对与所述受体有关的障碍的治疗
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
WO2014011926A1 (fr) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comportant des statines, des biguanides et d'autres agents pour réduire un risque cardiométabolique
US11007175B2 (en) 2015-01-06 2021-05-18 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
US11884626B2 (en) 2015-06-22 2024-01-30 Arena Pharmaceuticals, Inc. Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compound1) for use in S1P1 receptor-associated disorders
US11534424B2 (en) 2017-02-16 2022-12-27 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of primary biliary cholangitis
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor

Similar Documents

Publication Publication Date Title
WO2010074271A1 (fr) Agent thérapeutique pour le diabète
EP3004155B1 (fr) Composé peptidique
CN101801351B (zh) 包含阿格列汀和盐酸二甲双胍的固体制剂
US20230201184A1 (en) Compositions and methods for treating schizophrenia
CN102223884B (zh) 固体药物组合物
JP5732394B2 (ja) 錠剤
CN101384251B (zh) 含胰岛素敏化剂的固体制剂
JP2004123738A (ja) 徐放性製剤
TW201408290A (zh) 固態製劑
JP6122879B2 (ja) 固形製剤
HK1216757B (en) Peptide compound
HK1158543A (en) Solid pharmaceutical composition
EA040638B1 (ru) Фармацевтический состав, содержащий 2-((1-(2-(4-фторфенил)-2-оксоэтил)пиперидин-4-ил)метил)изоиндолин-1-он для лечения психоневрологического заболевания или расстройства сна, способ лечения психоневрологического заболевания или расстройства сна, таблетка и набор

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09835067

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 09835067

Country of ref document: EP

Kind code of ref document: A1